Merck & Co.'s modifications to the DFL for its proposed OTC switch of Mevacor in 2007 didn't convince FDA to approve what would have been the first nonprescription drug indicated for a chronic condition. • Source: Pegasus Research/FDA webinar
Explore how consumer health is evolving. On the go.
David Ridley hosts in-depth conversations with industry leaders.
